Results 61 to 70 of about 70,027 (183)

Hydroxychloroquine for therapeutic management of COVID-19: Breakthrough or Flash in the Pan? [PDF]

, 2021
Hydroxychloroquine is a drug used primarily to treat malaria, but in the 2020 pandemic, the drug caught the world's attention to treat the novel virus, SARS-CoV-2.
Jani, Ridhi
core   +1 more source

Will Hydroxychloroquine Still Be a Game-Changer for COVID-19 by Combining Azithromycin?

Frontiers in Immunology, 2020
Recent small-scale clinical trials have shown promising results in the use of hydroxychloroquine, an FDA approved anti-malaria drug, for the treatment of COVID-19.
Chunfeng Li, Genhong Cheng
doaj   +1 more source

The treatment of malaria with hydroxychloroquine

, 1955
The antimalarial drug, hydroxychloroquine (Plaquenil®,Winthrop ...
Mark T. Hoekenga
core   +1 more source

Effect of Hydroxychloroquine and Azithromycin on QT Interval Prolongation and Other Cardiac Arrhythmias in COVID-19 Confirmed Patients

Cardiovascular Therapeutics, 2021
Background. Hydroxychloroquine with or without azithromycin was one of the common therapies at the beginning of the COVID-19 pandemic. They can prolong QT interval, cause torsade de pointes, and lead to sudden cardiac death.
Seyed Parsa Eftekhar, Sohrab Kazemi, Mohammad Barary, Mostafa Javanian, Soheil Ebrahimpour, Naghmeh Ziaei   +5 more
doaj   +1 more source

Hydroxychloroquine Toxicity and Screening

, 2020
Dr.
Andrew G. Lee, MD; Lauren Nakhleh
core  

Disposition of the Enantiomers of Hydroxychloroquine in Patients with Rheumatoid-Arthritis Following Multiple Doses of the Racemate

, 1993
In eight patients with rheumatoid arthritis receiving racemic hydroxychloroquine, blood and urine concentrations of the enantiomers of hydroxychloroquine and its major metabolites were measured each month over the first 6 months of therapy.
AJ McLachlan, SE Tett, Tett, SE, Day, RO, DJ Cutler, McLachlan, AJ, Cutler, DJ, RO Day   +7 more
core   +1 more source

Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial

, 2021
Purpose: To study the efficacy of lopinavir-ritonavir and hydroxychloroquine in critically ill patients with coronavirus disease 2019 (COVID-19).
Gordon, AC, Swaidan, LA, Bonten, MJM, Beidh, FA, Arabi, YM, Annane, D, Nichol, AD, Murthy, S, Beasley, R, Derde, LPG, Berry, LR, Bhimani, Z, White, Hayden T., Beane, A, et al.   +14 more
core   +1 more source

Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study.

PLoS ONE, 2020
Hydroxychloroquine has been touted as a potential COVID-19 treatment. Tocilizumab, an inhibitor of IL-6, has also been proposed as a treatment of critically ill patients.
Andrew Ip, Donald A Berry, Eric Hansen, Andre H Goy, Andrew L Pecora, Brittany A Sinclaire, Urszula Bednarz, Michael Marafelias, Scott M Berry, Nicholas S Berry, Shivam Mathura, Ihor S Sawczuk, Noa Biran, Ronaldo C Go, Steven Sperber, Julia A Piwoz, Bindu Balani, Cristina Cicogna, Rani Sebti, Jerry Zuckerman, Keith M Rose, Lisa Tank, Laurie G Jacobs, Jason Korcak, Sarah L Timmapuri, Joseph P Underwood, Gregory Sugalski, Carol Barsky, Daniel W Varga, Arif Asif, Joseph C Landolfi, Stuart L Goldberg   +31 more
doaj   +1 more source

Toxidermie médicamenteuse sous hydroxychloroquine pour traitement systémique d´un syndrome de Goujerot Sjögren primaire: rapport de cas

The Pan African Medical Journal, 2021
Nous rapportons un cas d´exanthème maculo-papuleux apparu après une semaine de prise de l´hydroxychloroquine 400mg prescrite pour une atteinte articulaire d´un syndrome de Goujerot Sjögren primaire chez une patiente de 41 ans.
Ansumana Mohammed Keita, Mouna Zahlane, Laila Benjilali, Lamiaa Essaadouni   +3 more
doaj   +1 more source

Acute left ventricular failure in a patient with hydroxychloroquine-induced cardiomyopathy [PDF]

, 2011
We present the case of a 75-year-old woman with a medical history of rheumatoid arthritis treated with hydroxychloroquine, who was admitted with acute left-sided heart failure due to a hydroxychloroquine-induced cardiomyopathy as supported by ...
von Birgelen, C., H. P. C. M. Lambregts, I. L. Meek, C. von Birgelen, van der Wal, A.C., G. K. van Houwelingen, Toes, G.J., G. J. Toes, van Houwelingen, G.K., Hartmann, M., A. C. van der Wal, Lambregts, H.P.C.M., M. Hartmann, Meek, I.L.   +13 more
core   +1 more source